| Tchem | Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta |
Phosphorylates PtdIns and PtdIns4P with a preference for PtdIns. Does not phosphorylate PtdIns(4,5)P2. May be involved in EGF and PDGF signaling cascades.
The protein encoded by this gene belongs to the phosphoinositide 3-kinase (PI3K) family. PI3-kinases play roles in signaling pathways involved in cell proliferation, oncogenic transformation, cell survival, cell migration, and intracellular protein trafficking. This protein contains a lipid kinase catalytic domain as well as a C-terminal C2 domain, a characteristic of class II PI3-kinases. C2 domains act as calcium-dependent phospholipid binding motifs that mediate translocation of proteins to membranes, and may also mediate protein-protein interactions. The PI3-kinase activity of this protein is sensitive to low nanomolar levels of the inhibitor wortmanin. The C2 domain of this protein was shown to bind phospholipids but not Ca2+, which suggests that this enzyme may function in a calcium-independent manner. [provided by RefSeq, Jul 2008]
The protein encoded by this gene belongs to the phosphoinositide 3-kinase (PI3K) family. PI3-kinases play roles in signaling pathways involved in cell proliferation, oncogenic transformation, cell survival, cell migration, and intracellular protein trafficking. This protein contains a lipid kinase catalytic domain as well as a C-terminal C2 domain, a characteristic of class II PI3-kinases. C2 domains act as calcium-dependent phospholipid binding motifs that mediate translocation of proteins to membranes, and may also mediate protein-protein interactions. The PI3-kinase activity of this protein is sensitive to low nanomolar levels of the inhibitor wortmanin. The C2 domain of this protein was shown to bind phospholipids but not Ca2+, which suggests that this enzyme may function in a calcium-independent manner. [provided by RefSeq, Jul 2008]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Neoplasm Metastasis | 168 | 0.0 | 0.0 |
| Disease | Target Count | P-value |
|---|---|---|
| Chronic Lymphocytic Leukemia | 262 | 1.6e-10 |
| malignant mesothelioma | 3232 | 2.5e-07 |
| Waldenstrons macroglobulinemia | 765 | 1.1e-05 |
| intraductal papillary-mucinous adenoma (IPMA) | 2955 | 1.2e-04 |
| pituitary cancer | 1972 | 3.3e-04 |
| intraductal papillary-mucinous neoplasm (IPMN) | 3291 | 1.5e-03 |
| intraductal papillary-mucinous carcinoma (IPMC) | 2989 | 5.1e-03 |
| astrocytic glioma | 2597 | 1.5e-02 |
| ependymoma | 4679 | 2.5e-02 |
| lung cancer | 4740 | 3.4e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| ulcerative colitis | 1819 | 0.0 | 3.0 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Centronuclear myopathy | 27 | 3.071 | 1.5 |
| Disease | log2 FC | p |
|---|---|---|
| astrocytic glioma | -1.100 | 1.5e-02 |
| Chronic Lymphocytic Leukemia | -1.825 | 1.6e-10 |
| ependymoma | -1.300 | 2.5e-02 |
| intraductal papillary-mucinous adenoma (... | 1.800 | 1.2e-04 |
| intraductal papillary-mucinous carcinoma... | 1.800 | 5.1e-03 |
| intraductal papillary-mucinous neoplasm ... | 2.000 | 1.5e-03 |
| lung cancer | -1.600 | 3.4e-02 |
| malignant mesothelioma | -1.900 | 2.5e-07 |
| pituitary cancer | 1.400 | 3.3e-04 |
| Waldenstrons macroglobulinemia | -1.378 | 1.1e-05 |
CHEMBL2165017
pIC50 7.54
CHEMBL573339
pIC50 7.59
CHEMBL1765602
pIC50 7.61
CHEMBL538346
pIC50 8.00
CHEMBL230011
pKd 8.14
MSSTQGNGEHWKSLESVGISRKELAMAEALQMEYDALSRLRHDKEENRAKQNADPSLISWDEPGVDFYSK 1 - 70 PAGRRTDLKLLRGLSGSDPTLNYNSLSPQEGPPNHSTSQGPQPGSDPWPKGSLSGDYLYIFDGSDGGVSS 71 - 140 SPGPGDIEGSCKKLSPPPLPPRASIWDTPPLPPRKGSPSSSKISQPSDINTFSLVEQLPGKLLEHRILEE 141 - 210 EEVLGGGGQGRLLGSVDYDGINDAITRLNLKSTYDAEMLRDATRGWKEGRGPLDFSKDTSGKPVARSKTM 211 - 280 PPQVPPRTYASRYGNRKNATPGKNRRISAAPVGSRPHTVANGHELFEVSEERDEEVAAFCHMLDILRSGS 281 - 350 DIQDYFLTGYVWSAVTPSPEHLGDEVNLKVTVLCDRLQEALTFTCNCSSTVDLLIYQTLCYTHDDLRNVD 351 - 420 VGDFVLKPCGLEEFLQNKHALGSHEYIQYCRKFDIDIRLQLMEQKVVRSDLARTVNDDQSPSTLNYLVHL 421 - 490 QERPVKQTISRQALSLLFDTYHNEVDAFLLADGDFPLKADRVVQSVKAICNALAAVETPEITSALNQLPP 491 - 560 CPSRMQPKIQKDPSVLAVRENREKVVEALTAAILDLVELYCNTFNADFQTAVPGSRKHDLVQEACHFARS 561 - 630 LAFTVYATHRIPIIWATSYEDFYLSCSLSHGGKELCSPLQTRRAHFSKYLFHLIVWDQQICFPVQVNRLP 631 - 700 RETLLCATLYALPIPPPGSSSEANKQRRVPEALGWVTTPLFNFRQVLTCGRKLLGLWPATQENPSARWSA 701 - 770 PNFHQPDSVILQIDFPTSAFDIKFTSPPGDKFSPRYEFGSLREEDQRKLKDIMQKESLYWLTDADKKRLW 771 - 840 EKRYYCHSEVSSLPLVLASAPSWEWACLPDIYVLLKQWTHMNHQDALGLLHATFPDQEVRRMAVQWIGSL 841 - 910 SDAELLDYLPQLVQALKYECYLDSPLVRFLLKRAVSDLRVTHYFFWLLKDGLKDSQFSIRYQYLLAALLC 911 - 980 CCGKGLREEFNRQCWLVNALAKLAQQVREAAPSARQGILRTGLEEVKQFFALNGSCRLPLSPSLLVKGIV 981 - 1050 PRDCSYFNSNAVPLKLSFQNVDPLGENIRVIFKCGDDLRQDMLTLQMIRIMSKIWVQEGLDMRMVIFRCF 1051 - 1120 STGRGRGMVEMIPNAETLRKIQVEHGVTGSFKDRPLADWLQKHNPGEDEYEKAVENFIYSCAGCCVATYV 1121 - 1190 LGICDRHNDNIMLKTTGHMFHIDFGRFLGHAQMFGNIKRDRAPFVFTSDMAYVINGGDKPSSRFHDFVDL 1191 - 1260 CCQAYNLIRKHTHLFLNLLGLMLSCGIPELSDLEDLKYVYDALRPQDTEANATTYFTRLIESSLGSVATK 1261 - 1330 LNFFIHNLAQMKFTGSDDRLTLSFASRTHTLKSSGRISDVFLCRHEKIFHPNKGYIYVVKVMRENTHEAT 1331 - 1400 YIQRTFEEFQELHNKLRLLFPSSHLPSFPSRFVIGRSRGEAVAERRREELNGYIWHLIHAPPEVAECDLV 1401 - 1470 YTFFHPLPRDEKAMGTSPAPKSSDGTWARPVGKVGGEVKLSISYKNNKLFIMVMHIRGLQLLQDGNDPDP 1471 - 1540 YVKIYLLPDPQKTTKRKTKVARKTCNPTYNEMLVYDGIPKGDLQQRELQLSVLSEQGFWENVLLGEVNIR 1541 - 1610 LRELDLAQEKTGWFALGSRSHGTL 1611 - 1634 //
